AR and neoplasm: According to recently revealed interim clinical results from Arvinas, ARV-110 has demonstrated potential performance in a phase 1 clinical trial for patients with very-late-stage meta-static castration-resistant prostate cancer (mCRPC), with PSA reductions of >50% noted at doses greater than 280 mg; however, earlier research and numerous pre-treatments may cause tumor resistance to targeted androgen receptor (AR) therapy, which would reduce its effectiveness.